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Abstract Passive transfer of antibodies has long been consid-
ered a potential treatment modality for infectious diseases,
including HIV. Early efforts to use antibodies to suppress
HIV replication, however, were largely unsuccessful, as the
antibodies that were studied neutralized only a relatively nar-
row spectrum of viral strains and were not very potent. Recent
advances have led to the discovery of a large portfolio of
human monoclonal antibodies that are broadly neutralizing
across many HIV-1 subtypes and are also substantially more
potent. These antibodies target multiple different epitopes on
the HIV envelope, thus allowing for the development of anti-
body combinations. In this review, we discuss the application
of broadly neutralizing antibodies (bNAbs) for HIV treatment
andHIVeradication strategies.We highlight bNAbs that target
key epitopes, such as the CD4 binding site and the V2/V3-
glycan-dependent sites, and we discuss several bNAbs that are
currently in the clinical development pipeline.
Keywords HIV .Antibody .Broadlyneutralizingantibodies .
HIV pathogenesis . Reservoir . bNAb . Eradication . HIV/
AIDS . Review
Introduction
More than 78million people have been infected with HIV, and
39 million people have died since the beginning of the AIDS
epidemic [1]. In 2013, there were 1.5 million deaths attribut-
able to HIV infection and 6000 new HIV infections per day.
The great majority of new infections (68 %) occurred in sub-
Saharan Africa, with large proportions of AIDS-related deaths
occurring throughout the world, including in Nigeria (14 %),
South Africa (13 %), India (8 %), and the Russian Federation
(2 %). One reason that such high rates of AIDS-related deaths
continue to occur globally, despite the advent of drugs that are
highly effective at suppressing HIV replication, is that only
two in five people living with HIV actually have access to
antiretroviral therapy (ART). Moreover, ART does not cure
HIV infection and must be maintained for a lifetime. Even in
the USA, only 30 % of the 1.2 million people living with HIV
have suppressed HIV to undetectable levels, despite the fact
that most HIV-infected people in the USA have access to ART
[2]. As a result, there has been no decline in AIDS-related
deaths in the USA for over a decade. Antiretroviral therapy
therefore is necessary but not sufficient to end the global
AIDS epidemic.
The recent discovery of highly potent, broadly neutralizing,
HIV-specific monoclonal antibodies (bNAbs) provides a nov-
el class of potential therapeutic agents. It has long been known
that neutralizing antibodies can target the HIVenvelope (Env)
and effectively suppress viral replication in vitro [3]. Until
recently, however, bNAbs were few in number, targeted a
narrow spectrum of HIV strains, and were not potent enough
for practical use.
Over the last 5 years, the field has changed dramatically:
new developments in high throughput single-cell BCR ampli-
fication and novel soluble Env selection tools have led to the
isolation of new monoclonal antibodies with substantially
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increased potency and breadth. Phase 1 clinical trials of two
CD4 binding site-specific bNAbs, VRC01 and 3BNC117,
have shown that these antibodies are well tolerated in HIV-
infected and HIV-uninfected adults, and 3BNC117 has been
shown to provide antiviral activity in humans [4••, 5••].
Moreover, preclinical data in the non-human primate model
using the V3 glycan-dependent bNAb PGT121 demonstrated
reduction of proviral DNA in both blood and tissues [6••]. As
a result, several laboratories are exploring the possibility that
bNAbs may contribute to HIV eradication strategies.
Early Efforts Utilizing Antibodies to Treat HIV
Passive Immunotherapy with Pooled Plasma
from HIV-Infected Donors
Passive transfer of anti-HIVantibodies has been tested for the
treatment of HIV since the late 1980s, when investigators
attempted to suppress viral replication with infusions of
inactivated hyperimmune plasma pooled from HIV-infected
donors [7–12]. Jackson et al. (1988) demonstrated in six sub-
jects that infusions of plasma from donors with high titers of
anti-p24 (HIV core antigen) led to clearance of p24 antigen in
the blood for up to 11 weeks [9]. Karpas et al. (1988) showed
similar results in 10 subjects following infusion of hyperim-
mune plasma [10, 11]. However, follow-up studies that were
randomized and placebo-controlled were less clear in their
findings. Jacobson et al. (1993) showed in 65 subjects that
monthly infusions of anti-HIV hyperimmune plasma as com-
pared with placebo had no impact on quantitative HIV cul-
tures, CD4 counts, incidence of opportunistic infections, or
death [7]. Still, a trend towards longer survival and delayed
opportunistic infections was observed. Levy et al. (1994) also
showed that in a randomized, placebo-controlled trial of 220
subjects, infusions of hyperimmune plasma led to improved
clinical outcomes only in subjects with CD4 counts 50–200
cells/mm3 who received the highest dose [13]. In this subset of
subjects, a significant increase in CD4 count was observed,
but overall, differences in mortality did not reach statistically
significance. On the other hand, Vittecoq et al. (1995) ob-
served that passive immunotherapy did lead to a significant
delay in the appearance of the first AIDS-defining event in 86
subjects as compared to placebo when given more frequently
(every 2 weeks), as well as a mortality benefit [8]. A
retrospective analysis of changes in plasma HIV RNA
confirmed that after the third dose, there was a signifi-
cant difference in viral load between the passive immu-
notherapy and placebo groups [14]. These early studies
provided the key observat ion that infusion of
HIV-specific antibodies can lead to reductions in plasma
virus that may lead to clinical benefits.
Passive Immunotherapy with First-Generation Broadly
Neutralizing Antibodies
Immunotherapy with anti-HIVantibodies changed in focus in
the late 1990s, when the first bNAbs became available for
clinical testing. Most clinical trials focused on the three mono-
clonal antibodies 2G12, 2F5, and 4E10 [15–21]. 2F5 recog-
nizes the ELDKWA motif on the ectodomain of gp41 [22];
2G12 is directed against N-linked glycans in the C2, C3, V4,
and C4 domains of gp120 [23, 24]; and 4E10 binds to a linear
epitope (NWFDIT) that is adjacent to the 2F5 binding site on
gp41 [25]. Armbruster et al. (2002, 2004) showed in two
studies that combinations of these antibodies were safe and
well tolerated in 15 HIV-infected subjects at doses of up to
14 g of antibody over a 4-week period [15, 16], and follow-up
analyses by Stiegler at al. (2002) demonstrated that combina-
tion of these bNAbs led to reductions in plasma HIV RNA of
up to 1.46 log10 copies/ml in a subset of volunteers [17].
Based on these results in viremic HIV-infected subjects,
Trkola et al. (2005) conducted a proof-of-principle study to
evaluate the effect of the three bNAb cocktail (2G12, 2F5,
4E10) in HIV-infected subjects whose virus was well con-
trolled on ART to evaluate their potential impact following
cessation of ART [18]. The hypothesis was that the antibodies
might work in tandemwith host immune responses to delay or
to prevent viral rebound. Fourteen HIV-infected participants
(8 chronic, 6 acute) on ART received 13 passive infusions of
the three bNAb cocktail over 11 weeks, with treatment inter-
ruption commencing after the first infusion. Only two of eight
chronically treated subjects showed a delay in viral rebound
following passive immunization when compared to the kinet-
ics of previous structured treatment interruptions. However,
among the acutely treated subjects, there was a significant
difference in the time to viral rebound as compared to
a historical control group (median 8 vs. 3.75 weeks),
and efficacy appeared to correlate with higher plasma
concentrations of 2G12. This study also revealed a ma-
jor limitation of the three bNAb cocktail: 12 of the 14
subjects developed resistance to 2G12 in rebounding
virus, highlighting the ease with which viral escape
can emerge. This result also suggested that 2G12 was
the most (or only) active Ab in the cocktail.
Mehandru et al. (2007) also tested the three bNAb cocktail
in HIV-infected subjects on ART (N=10) [26]. Instead of
stopping ART after the first infusion, however, ARTwas con-
tinued through three infusions and then stopped. The hypoth-
esis was that the immediate interruption of therapy done by
Trkola et al. might not have allowed adequate time for anti-
bodies to reach all tissue compartments of the body. Results
were very similar; 8 of 10 subjects demonstrated viral rebound
despite 16 weeks of treatment, although the kinetics of re-
bound was delayed compared to historical data. Again, viral
escape with resistance to 2G12 was observed in 7/8 of
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subjects, particularly with mutations at N-linked glycosylation
sites.
Current Efforts to Develop Antibodies for HIV
Eradication
In the last 5 years, there has been an explosion in the number
of potent HIV-specific bNAbs, several of which are being
explored as therapeutic and prophylactic candidates.
Advances in high throughput single-cell B cell receptor am-
plification, as well as new soluble trimeric Envs that can be
used to select bNAbs, have led to the identification of multiple
bNAbs with increasing potency and breadth. The bNAbs that
are the most advanced in clinical development are outlined
below.
CD4 Binding Site Antibodies
HIVentry into target cells is dependent on viral attachment to
the CD4 receptor and is mediated through binding to a con-
formational epitope on the trimeric Env glycoprotein termed
the CD4 binding site (CD4bs). Antibodies that are specific to
the CD4bs can therefore block viral entry and inhibit viral
replication. Moreover, the CD4bs is functionally conserved
across diverse HIV strains, and thus anti-CD4bs antibodies
can be extremely broad. Many CD4bs antibodies have now
been isolated from human donors, and they share common
structural features, such as heavy chain mimicry of the CD4
receptor [27–29].
One of the first CD4bs antibodies identified was VRC01,
which was originally isolated from an HIV-infected individual
that had been living with untreated infection for over 15 years
[30]. Like other CD4bs antibodies, VRC01 is highly somati-
cally mutated, having evolved in response to continual virus
escape over many years [31]. Using a panel of 190 Env-
pseudotyped viral strains representing all major clades and
circulating recombinants, Wu et al. (2010) demonstrated that
VRC01 neutralized 91 % of pseudovirions at a half maximal
inhibitory concentration (IC50) of <50 μg/ml, and neutralized
72 % of primary isolates at an IC50 of <1 μg/ml [30].
Preclinical challenge studies in non-human primates con-
firmed that VRC01 had protective activity in vivo as well [32].
Based on these in vitro and preclinical data, the Vaccine
Research Center (VRC) at the National Institute of Allergy
and Infectious Diseases embarked on a clinical development
program of VRC01. One emphasis of the program is to test
whether VRC01 might have potential as a prophylactic agent,
particularly in the setting of preventing perinatal transmission
of HIV [33]. In 2015, Ledgerwood et al. reported the results of
the first clinical trial testing VRC01 in humans (VRC602)
[4••]. In this study, 28 healthy adults received varying doses
of VRC01 ranging from 5 up to 40 mg/kg given as an
intravenous infusion, as well as subcutaneously in some sub-
jects at 5 mg/kg. Doses were given either once or twice,
28 days apart, and a subset of subjects received placebo.
This study showed that among 43 administrations of VRC01
throughout the study, there were no serious adverse events,
and local and systemic solicited reactions were mild. Subjects
also did not develop anti-VRC01 antibodies, even though
some possessed IgG1 GM allotypes that mismatched with
VRC01. The pharmacokinetic analysis showed that VRC01
had a half-life of 15 days when given i.v. with 28-day trough
levels that ranged from 35 to 89 μg/ml depending on the dose
and frequency of administration. Based on preclinical data
that had shown VRC01 was 50 % protective at concentrations
of 18–28 μg/ml [32], the authors concluded that potentially
protective VRC01 serum levels were observed in their sub-
jects for up to 8 weeks following a second infusion. The po-
tential utility of VRC01 in therapeutic and eradication strate-
gies is currently being explored in HIV-infected subjects on
and off antiretroviral treatment, and a phase 2b efficacy study
to evaluate VRC01 for prevention of acquisition of HIV is
expected to start soon.
3BNC117 is a CD4bs-specific antibody that was isolated
from a viremic controller, i.e., an HIV-infected individual with
low plasma HIV RNA in the absence of antiretroviral therapy
[34]. Scheid et al. (2011) demonstrated that 3BNC117 neutral-
ized 195 out of 237 HIV-1 strains with an average IC50 of
0.08 μg/ml [34]. Shingai et al. (2013) reported that 3BNC117,
when given as monotherapy to two non-human primates at a
dose of 10 mg/kg, induced a rapid decline of plasma viremia
that persisted until 20 days following infusion; results were
improved when 3BNC117 was given in combination with the
V3 glycan-dependent antibody 10-1074 [35•].
Caskey et al. (2015) then tested the safety and antiviral
activity of 3BNC117 when given as an intravenous infusion
to 12 HIV-uninfected and 17 HIV-infected adults [5••]. The
study was structured as a dose-escalation trial of a single in-
travenous infusion of 1, 3, 10, or 30 mg/kg of 3BNC117.
Caskey et al. demonstrated that 3BNC117, like VRC01, was
well-tolerated at all doses. Interestingly, the pharmacokinetic
profile of 3BNC117 was different between HIV-infected and
HIV-uninfected subjects, with the half-life of the antibody of
9 days in HIV-infected subjects as compared to 17 days in
HIV-uninfected subjects. These data suggest that 3BNC117
is cleared more rapidly in the setting of viremia, possibly
due to antibodies rapidly binding virions followed by clear-
ance of antigen-antibody complexes. This study also showed
that 3BNC117’s antiviral effect was dose dependent. At 1 and
3mg/kg, 3BNC117was largely ineffective at reducing plasma
HIV RNA, while 30 mg/kg led to a transient 0.8–2.5 log10
drop in plasma HIV RNA. The starting viral load of subjects
appeared to influence the magnitude of response and the du-
ration of suppression, and the sensitivity of the circulating
virus to 3BNC117 was critical. Analysis for viral escape
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showed that two of five individuals tested who received the
30mg/kg dose developed >5-fold reduction of 3BNC117 neu-
tralization sensitivity by 28 days after antibody infusion. The
remaining three of five individuals showed little reduction in
neutralization sensitivity, suggesting that 3BNC117 resistance
can occur quickly but not in all subjects.
V3 Glycan-Dependent Antibodies
PGT121 is a monoclonal antibody isolated in 2011 from an
African donor that targets a V3 glycan-dependent site on the
HIVenvelope [36]. PGT121 is distinct from other V3-specific
monoclonal antibodies, like KD-247, because it does not bind
simply to the GPGR region of V3 [37]. Instead, PGT121 has a
long heavy chain complementarity determining region (CDR)
that forms an antibody binding site with two functional sur-
faces. Structural studies suggest that PGT121 inhibits CD4
binding to gp120 despite the fact that it does not engage the
classically described CD4 binding site [38]. Instead, PGT121
likely interferes with Env receptor engagement by an alloste-
ric mechanism in which key structural elements, such as the
V3 base, the N332 oligomannose glycan, and surrounding
glycans, including a putative V1/V2 glycan, are locked into
a conformation that obstructs CD4 binding [38]. By interfer-
ing with a highly conserved function required for viral entry,
PGT121 has excellent potency and breadth of activity. For
example, Walker et al. (2011) demonstrated that PGT121
had a median IC50 of 0.03 μg/ml when tested against a panel
of 162 HIV pseudoviruses; this potency was a log higher than
that observed for the CD4-binding site antibody VRC01
(0.32 μg/ml). In addition, Walker et al. demonstrated that
PGT121 was able to neutralize 70 % of pseudoviruses tested.
Our laboratory investigated the therapeutic efficacy of
PGT121 by giving a single infusion of 10 mg/kg PGT121
alone, 3BNC117 alone, or the control monoclonal antibody
DEN3 in rhesus macaques that were chronically infected with
SHIV-SF162P3 [6••]. PGT121 alone resulted in rapid virolog-
ic control to undetectable levels by day 7, followed by viral
rebound by days 42–56 in most animals when serum PGT121
titers dropped to undetectable levels. Rare animals with the
lowest starting viral loads exhibited long-term virologic con-
trol. PGT121 also appeared to reduce proviral DNA in both
blood and tissues [6••]. Moreover, PGT121 resulted in reduc-
tions in the percentage of PD-1+Ki67+ Gag-specific CD8+
and CD4+ T lymphocytes, respectively, suggesting that the
antibody infusion may have improved the function of host
virus-specific T cell responses, likely as a result of the reduc-
tion of circulating viral antigens [6••]. This conclusion was
supported by the fact that setpoint viral loads following viral
rebound were 0.6 log lower than setpoint viral loads prior to
mAb infusion, suggesting that mAb infusion may have mod-
ulated host immune function [6••].
Viral rebound in the above experiment occurred after a
median of 56 days when antibody titers declined to undetect-
able levels. Rebound virus was sequenced in all animals and
no viral escape variants were detected in any animals, suggest-
ing that PGT121 may have a relatively high bar for the devel-
opment of resistance. Further structural and binding assess-
ments have suggested that PGT121 can make at least four
contacts on the Env surface and is not entirely dependent on
the N332 glycan. This promiscuous glycan binding results in
the need for multiple mutations to escape from this antibody in
certain settings [39, 40].
These studies demonstrated that PGT121 exhibited antivi-
ral activity in viremic, SHIV-infected rhesus monkeys, but
these data did not directly show targeting of the viral reservoir.
To address this question, ongoing studies are evaluating
PGT121 in ART-suppressed, SHIV-infected rhesus monkeys.
PGT121 is also being advanced into clinical trials, with plans
for first-in-human, phase 1 testing in HIV-uninfected and
HIV-infected adults in 2016. 10-1074 is a related V3 glycan-
dependent antibody that is also undergoing phase 1 testing.
V2 Glycan-Dependent Antibodies
CAP256 is a recently described bNAb isolated from an HIV-
infected individual in South Africa who had been infected
(and subsequently superinfected) with HIV-1 subtype C for
approximately 5 years before initiating antiretroviral therapy
[41]. Moore et al. (2011) demonstrated that CAP256 had a
bias towards neutralizing subtype C and A viruses, in some
cases with remarkable potency. Epitope mapping studies
showed that CAP256 bound a quaternary epitope found on the
trimeric form of the envelope glycoprotein that was dependent
on residues 159 to 171 in the V2 loop. Analysis of similar
antibodies in this class revealed that the long heavy-chain
CDR region 3 loops pierce the HIV-1 glycan shield to bind
to the quaternary epitope at the apex of the HIV-1 spike where
the V1V2 regions of two gp120 protomers meet [42, 43]. Reh
et al. (2015) demonstrated that two CAP256 variants
(VRC26.08 and VRC26.09) were also able to inhibit cell-cell
virus spread [44].
PGDM1400 was recently identified by Sok et al. (2014) by
using trimeric HIV-1 envelope (BG505 SOSIP.664) as bait to
select memory B cells from an HIV-infected donor by single-
cell sorting [45•]. PGDM1400 exhibited exceptional breadth
and potency. For example, PGDM1400 neutralized 83 % of
viruses of a cross-clade 106-virus panel, with a median IC50 of
0.003 μg/ml. Structural studies revealed that PGDM1400, like
CAP256, binds to the trimer apex via a very long (34-residue)
CDRH3 arm. Moreover, the combination of PGDM1400+
PGT121 neutralized 98 % of tested global viruses at a median
IC50 of 0.007 μg/ml. These data suggest the potential of bNAb
cocktails for global coverage.
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The Future of Broadly Neutralizing Antibodies
for HIV Eradication
The current generation of bNAbs against HIV are notable for
their potency and breadth, and they have been shown to lead
to declines in plasma viremia in preclinical studies and in
phase 1 clinical trials [4••, 5••, 6••, 35•]. However, the ability
of bNAbs to target the latent viral reservoir and to contribute
to viral eradication strategies remains unknown. In vitro data
has shown that VRC01 and PGT121 can inhibit viral replica-
tion produced from reactivated reservoir cells [46], and mouse
studies have shown that FcgR-mediated effector function is
required for 3BNC117 to block viral entry and suppress vire-
mia [47]. Moreover, PGT121 infusion in SHIV-infected non-
human primates reduced proviral DNA [6••].
Nevertheless, it is likely that bNAbs will need to be used in
combination with latency reversing agents, such as histone
deacetylase inhibitors (HDACi) or TLR agonists [48, 49].
Halper-Stromberg et al. (2014) tested the concept of combi-
nation bNAb/LRA treatment by administering the bNAbs
3BNC117, 10-1074, and PG16 together with vorinostat
(HDACi), I-BET151 (BET protein inhibitor), and CTLA4 (a
T cell inhibitory pathway blocker) in humanized HIV-infected
mice [50]. The authors found that only 10 of 23 mice that had
antibody-induced suppression went on to viral rebound fol-
lowing LRA treatment, and of the remaining 57% ofmice that
did not rebound, all had undetectable cell-associated viral
RNA. Studies in non-human primates are ongoing to evaluate
various bNAb/LRA combination treatments in animals with
an intact immune system that may contribute to Fc-mediated
cell killing. Klein et al. (2014) reported in humanized mice
that bNAbs functioned together with autologous antibodies to
achieve durable viral suppression [51]. The strategy of com-
bining bNAbs with LRAs will also be investigated in humans
in the next several years.
Conclusions
The concept of using antibodies against HIV to suppress viral
replication has been around for many years, but early efforts
using hyperimmune plasma from HIV-infected donors and
bNAbs with low potency and narrow breadth were largely
disappointing. The advent of multiple new bNAbs with sub-
stantially greater potency and breadth has led to greatly ex-
panded possibilities. Preclinical studies have shown that cer-
tain bNAbs can reduce viral loads and also lead to reductions
of proviral DNA, particularly when given with latency rever-
sal agents. Most importantly, early clinical trials have shown
that bNAbs are safe, well-tolerated, and have antiviral activity
in HIV-infected subjects. Additional clinical trials are planned
for the coming years.
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